CytomX Therapeutics Inc (CTMX) stock forecast · rev $11.7M
CytomX Therapeutics Inc (CTMX) is a biotechnology company listed on US.
This CTMX forecast page states what the cached financials imply — not a price target and not a guarantee. CytomX Therapeutics Inc outlooks on Lician start from reported revenue and the latest filing, then you decide.
Latest reported CTMX revenue for 2026-06-30 was $11.7M. Net income was -$38.9M. Revenue was up 13.8% from 2026-03-31 to 2026-06-30. CTMX currently screens at market cap $653.1M.
The near-term path: Revenue was up 13.8% from 2026-03-31 to 2026-06-30. A forecast that ignores that change is just a story.
CTMX currently screens at market cap $653.1M. Stretching today's multiple into 2026 without a filing reason is how thin forecast pages get ignored.
When the next CTMX 10-Q or 8-K lands, this outlook should move. Until then the SEC page is the source.
Not a prediction market. For the live quote and the full model, use the CTMX stock page.
Not investment advice.